Doctors Without Borders (Médecins Sans Frontières, or MSF) is urging pharmaceutical developers and global health policymakers to establish transparent access plans, fair pricing, and pediatric treatment strategies for three experimental drugs being tested against the Bundibugyo Ebola virus strain in the Democratic Republic of the Congo.
Doctors Without Borders Demands Access Plans for Experimental Ebola Drugs
The medical humanitarian organization released a technical brief warning that past outbreaks demonstrate clinical trial success alone does not guarantee timely or affordable patient access. Without early intervention on supply chains and intellectual property licensing, communities risk facing severe deployment delays and reliance on ad hoc charitable donations.
Active Trials Target Bundibugyo Strain in Ituri Province
The Democratic Republic of the Congo is currently hosting two major clinical evaluations—known as the PARTNERS and EBO-PEP trials—to assess the safety and efficacy of three specific therapeutic candidates: MBP134, remdesivir, and obeldesivir.
Mapp Biopharmaceutical develops MBP134, while Gilead Sciences develops both remdesivir and obeldesivir. Public and philanthropic funding sources have supported the development and clinical testing of all three medications. MSF participates directly in the WHO-sponsored PARTNERS trial through its Ebola treatment center in Bunia, located in the DRC’s Ituri province.
Despite active patient recruitment and trial progression, publicly available data regarding manufacturing capacity, pricing frameworks, and licensing agreements remains sparse.
Lessons From Past Outbreaks and the Risk of Delay
Mónica Rull, deputy executive director of MSF Access, emphasized that relying on reactive measures after a drug proves effective leaves vulnerable populations at the mercy of commercial timelines.
Public health advocates point out that past health emergencies routinely suffered from bottlenecks where successful experimental treatments remained trapped behind non-transparent corporate decisions, leaving frontline medical providers without sufficient stockpiles during acute surges.
Concrete Demands Issued in New MSF Technical Brief
The MSF technical brief—titled “Therapeutics for the 2026 Bundibugyo Ebola Disease Outbreak: Access Gaps and Recommendations”—sets out concrete demands for stakeholders across the pharmaceutical and global health sectors.
- Transparent Agreements: Funders, researchers, and policymakers must bake enforceable access conditions directly into clinical trial contracts before efficacy is officially established.
- Strategic Stockpiling: Developers must plan for adequate manufacturing volume and sustainable supply chains to avoid last-minute distribution bottlenecks.
- Pediatric Integration: Treatment development programs must explicitly include children in their clinical design and access roadmaps rather than retrofitting protocols after adult trials conclude.
Current Status of Experimental Candidate Medications
Because MBP134, remdesivir, and obeldesivir remain under clinical evaluation, none of these candidates are currently authorized for routine clinical use outside of approved trial protocols. Medical authorities continue to monitor trial data as international organizations press for policy adjustments to safeguard future outbreak responses.